Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish

Shares of Bristol-Myers Squibb Co BMY have lost more than 10 percent since the start of 2016 and are nearly flat over the past year. A lack of growth in Bristol-Myers' stock over the past year hasn't deterred the Vetr crowd. The crowd-sourced stock rating platform upgraded the stock's rating to 4.5-stars out of a possible 5-stars. In fact, shares have risen to $61.71 since the prior rating of 4.0-stars was issued 14 days ago. Related link: Here's how crowdsourced ratings can beat the market.

In addition to an upgrade to bull territory, 83 percent of the crowd's ratings are bullish and the crowd sourced price target of $69.74 implies a potential upside of nearly 14 percent. Héctor Garcia, a member of the Vetr crowd, commented 10 days ago that Bristol-Myers' stock is trading below its 50 and 200-day moving average. The crowd member added that while this may be a bullish signal, the current market condition for healthcare stocks is "less than favorable." As such, Bristol-Myers' stock is more appropriate for a longer-term investor that can stomach near-term volatility.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasCrowdsourcingAnalyst RatingsTrading IdeasGeneralCrowd Sourced Stock Ratingshealthcare stocksVetrVetr Crowd
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!